ReviewBritish journal of clinical pharmacology2018
Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.
Review in British journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 137 citations in OpenAlex.
- [Expert recommendations for magnetic resonance imaging of muscle disorders].Radiologie (Heidelberg, Germany) · 2024Guideline
- Systematic review: investigating the added diagnostic value of gadolinium contrast agents for osteomyelitis in the appendicular skeleton.Skeletal radiology · 2022Pooled it
- Pharmacokinetics and safety of gadopiclenol in Japanese healthy volunteers.Japanese journal of radiology · 2025Trial
- Native T1 mapping for assessment of the perilesional zone in metastases and benign lesions of the liver.Scientific reports · 2020Trial
- Effect of liver fibrosis on gadolinium retention from gadodiamide, gadobutrol, and gadoxetate disodium in rats.Japanese journal of radiology · 2026Article
- Fe-doped carbon dots as dual-modeNanoscale · 2026Article
- Challenges in Controlled Doping of NaMnFACS omega · 2026Article
- Synthesis, Characterization, and Magnetic Properties of Fe(BIP)Pharmaceuticals (Basel, Switzerland) · 2026Article
- Gadolinium toxicity: mechanisms, clinical manifestations, and nanoparticle role.Archives of toxicology · 2025Review
- Ultra-high temporal resolution 4D angiography using arterial spin labeling with subspace reconstruction.Magnetic resonance in medicine · 2025Article
- Effect of EuRSC advances · 2025Article
- Editorial: Magnetic resonance imaging contrast agents: the safety of gadolinium.Frontiers in toxicology · 2025Article
- Gadolinium Contrast Agent Deposition in Children.Journal of magnetic resonance imaging : JMRI · 2025Review
- Comparative Evaluation of Lower Gadolinium Doses for MR Imaging of Meningiomas: How Low Can We Go?AJNR. American journal of neuroradiology · 2024Article
- [Expert recommendations for magnetic resonance imaging of muscle disorders].Der Nervenarzt · 2024Review
- Gadolinium contrast agents- challenges and opportunities of a multidisciplinary approach: Literature review.European journal of radiology open · 2023Review
- Evaluation of methemoglobin as an intravascular contrast agent: T1 relaxation time effect in a rabbit model.Magnetic resonance imaging · 2023Article
- Comparison of Methemoglobin, Deoxyhemoglobin, and Ferrous Nitrosyl Hemoglobin as Potential MRI Contrast Agents.Annals of biomedical engineering · 2023Article
- Cobalt Iron Oxide (CoFeVeterinary sciences · 2023Article
- Novel Gadolinium-Free Ultrasmall Nanostructured Positive Contrast for Magnetic Resonance Angiography and Imaging.Nano letters · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Every year, approximately 30 million magnetic resonance imaging scans are enhanced with gadolinium-based contrast agents (GBCAs) worldwide. Although the development of nephrogenic systemic fibrosis in patients with renal impairment is well-documented, over recent years it has become apparent that exposure to GBCAs can potentially result in gadolinium deposition within human bone and brain tissue even in the presence of normal renal function. This review will address some of the controversies surrounding the safety of GBCA administration based on evidence from in vivo experiments, animal studies and clinical studies. We additionally evaluate the potential risk of toxicity from exposure to gadolinium in light of new guidance published by the US Food and Drug Administration and the European Medicines Agency, and discuss whether gadolinium deposition disease exists as a new diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.